VRT-325 is a novel small molecule discovered by screening a compound library designed to address the genetic defect in cystic fibrosis (CF) caused by the deltaF508 mutation in CFTR. VRT-325 belongs to a class of compounds that promote deltaF508-CFTR efflux from the endoplasmic reticulum and restores chloride transport levels in epithelial cells of CF-derived bronchi[1].
Molecular Weight:
510.65
Purity:
99.15
CAS Number:
[815592-21-3]
Formula:
C27H34N4O4S
Target:
CFTR
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
